In the BioHarmony Drug Report Database

"Preview" Icon

Ledipasvir

Harvoni (ledipasvir) is a small molecule pharmaceutical. Ledipasvir was first approved as Harvoni on 2014-10-10. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Harvoni’s patents are valid until 2034-01-30 (FDA).

 

Trade Name

 

Harvoni
 

Common Name

 

ledipasvir
 

ChEMBL ID

 

CHEMBL2374220
 

Indication

 

chronic hepatitis c, hepatitis c
 

Drug Class

 

Antivirals: NS5A inhibitors

Image (chem structure or protein)

Ledipasvir structure rendering